HomeMedical Oncology
Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
Would you continue ruxolitinib in combination with HMA plus venetoclax in myelofibrosis at the time of transformation to AML?
1 Answers
Mednet Member
Medical Oncology · Massachusetts General Hospital
That is a good question. It would be difficult to give these three agents together as cytopenias would be very difficult to manage. In addition, it’s worth mentioning there are no data for this triplet and these drugs are not approved to be used together. That being said, there are some scenarios we...
Will you use or have you been using the IPSS-M as the primary way to risk-stratify patients with MDS to determine use of hypomethylating agents?
1
1 AnswersMednet Member
Medical Oncology · UC San Diego Health
For the last 10 years, the IPSS-R has been the gold standard for risk stratification of patients with MDS. It is used by the NCCN guidelines to split patients into lower or higher risk groups, each with its own distinct treatment recommendations. The IPSS-R has been used to select patients for clini...